

Unless otherwise defined in this announcement, terms defined in the prospectus dated 26 June 2014 (the “**Prospectus**”) issued by Luye Pharma Group Ltd. (the “**Company**”) shall have the same meanings when used in this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement is not, and is not intended to be, an offer of securities of the Company for sale in the United States. The securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. There is not, and is not intended to be, any public offering of the securities described in this announcement in the United States.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to the requirement under section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Cap 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an invitation or offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 2186)

STABILISING ACTIONS AND END OF STABILISING PERIOD

END OF STABILISING PERIOD

The Company announces that the stabilising period in connection with the Global Offering ended on 1 August 2014, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

STABILISING ACTIONS

The stabilising actions undertaken by Citigroup Global Markets Asia Limited (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, during the stabilising period were:

- (i) over-allocations of an aggregate of 149,946,000 Shares in the International Offering, representing 15% of the number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;

- (ii) the borrowing of 149,946,000 Shares by the Stabilising Manager from Luye Investment pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering; and
- (iii) the full exercise of the Over-allotment Option by the Joint Global Coordinators for themselves and on behalf of the International Purchasers and the Joint Bookrunners on 15 July 2014 in respect of an aggregate of 149,946,000 Shares, representing 15% of the number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Share.

END OF STABILISING PERIOD

The Company makes this announcement pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Cap 571W of the Laws of Hong Kong) and announces that the stabilising period in connection with the Global Offering ended on 1 August 2014, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

STABILISING ACTIONS

The stabilising actions undertaken by Citigroup Global Markets Asia Limited (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, during the stabilising period were:

- (i) over-allocations of an aggregate of 149,946,000 Shares in the International Offering, representing 15% of the number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (ii) the borrowing of 149,946,000 Shares by the Stabilising Manager from Luye Investment pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering; and
- (iii) the full exercise of the Over-allotment Option by the Joint Global Coordinators for themselves and on behalf of the International Purchasers and the Joint Bookrunners on 15 July 2014 in respect of an aggregate of 149,946,000 Shares, representing 15% of the number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Share.

Details of the full exercise of the Over-allotment Option are more particularly described in the announcement of the Company dated 15 July 2014.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules. No new Shares or securities convertible into equity securities of the Company may be issued within six months from the Listing Date save for the situations set out in Rule 10.08 of the Listing Rules.

By order of the Board
Luye Pharma Group Ltd.
LIU Dian Bo
Executive Chairman

Hong Kong, 1 August 2014

As at the date of this announcement, the Executive Directors are Mr. LIU Dian Bo, Mr. YUAN Hui Xian, Mr. YANG Rong Bing and Ms. ZHU Yuan Yuan; the Non-Executive Directors are Mr. PAN Jian, Mr. LIU Dong and Ms. WANG Xin; and the Independent Non-Executive Directors are Mr. ZHANG Hua Qiao, Prof. LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.